Crossmark

Translational and clinical implications of the genetic landscape of prostate cancer

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2016.76

Published Online: 2016-06-01

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Spratt, Daniel E.

Zumsteg, Zachary S.

Feng, Felix Y.

Tomlins, Scott A.
License Information

Text and Data Mining valid from 2016-06-01
More Information

Article History

First Online: 1 June 2016

Competing interests

: F.Y.F. has acted as a consulted for, and received honoraria from Astellas, Celgene, GenomeDx Biosciences, Medivation and Myriad. The University of Michigan has been issued a patent on the use of ETS gene fusions in patients with prostate cancer, on which S.A.T. is listed as a co-inventor; similarly, a patent application on the use of <i>SPINK1</i> in patients with prostate cancer has also been filed. The diagnostic field of use has been licensed to Gen-Probe (California, USA), which has sublicensed rights to Ventana Medical Systems (Arizona, USA). S.A.T. has consulted for, and received honoraria from AbbVie, Astellas, Jannsen and Ventana Medical Systems. S.A.T. has had a sponsored research agreement with, and has received travel support from ThermoFisher Scientific/Life Technologies. S.A.T. is a co-founder and equity holder in Strata Oncology. D.E.S. and Z.S.Z. declare no competing interests.